Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Laboratory parameters for the MS, sarcopenia, and combined groups compared with the control group are presented in Table 2.Laboratory test data by groupVariablesControl (n = 174)MS (n = 122)PaSarcopenia (n = 89)PbCombined (n = 75)PcBMD (g/cm3)0.67 (0.57, 0.77)0.67 (0.57, 0.78)0.70.65 (0.56, 0.74)0.40.59 (0.52, 0.74)0.019VitD (ng/mL)55 (44, 73)52 (39, 61)0.00254 (41, 64)0.04951 (40, 66)0.014WBC (10^9/L)8.28 (6.74, 10.28)9.18 (7.33, 11.52)0.0078.83 (7.09, 10.40)0.49.07 (7.52, 11.76)0.013NE (10^9/L)6.32 (5.09, 8.12)7.31 (5.34, 9.28)0.0127.12 (5.47, 8.47)0.0827.39 (5.75, 10.27)0.002LYM (10^9/L)1.10 (0.85, 1.43)1.16 (0.89, 1.47)0.30.90 (0.69, 1.17) < 0.0011.03 (0.79, 1.33)0.084Hb (g/L)107 ± 18110 ± 190.089105 ± 190.4106 ± 19 > 0.9Plt (10^9/L)178 (145, 227)199 (158, 262)0.029188 (152, 261)0.3194 (159, 233)0.2TP (g/L)63.7 ± 6.264.9 ± 5.40.1063 ± 70.564.3 ± 6.50.5ALB (g/L)34.7 (32.2, 37.0)34.7 (32.7, 37.3)0.433.9 (31.0, 36.6)0.234.9 (31.7, 36.8) > 0.9TG (mmol/L)1.12 (0.86, 1.47)1.78 (1.19, 2.10) < 0.0010.95 (0.74, 1.31)0.0081.71 (1.12, 1.99) < 0.001HDL-C (mmol/L)1.08 (0.87, 1.28)0.89 (0.78, 1.05) < 0.0011.06 (0.87, 1.27) > 0.90.94 (0.86, 1.12)0.027BMD Bone Mineral Density; VitD Vitamin D; WBC White Blood Cell; NE Neutrophils; LYM Lymphocytes; Hb Hemoglobin; Plt Platelets; TP total protein; ALB Albumin; TG Triglycerides; HDL-C High-Density Lipoprotein CholesterolaBetween Control and MS groupsbBetween Control and Sarcopenia groupscBetween Control and Combined groups

Source: Preoperative and postoperative laboratory parameters. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Following these criteria, a final cohort of 460 patients was selected for analysis (Fig.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Effect of sarcopenia combined with Metabolic Syndrome (MS) on the prognosis of intertrochanteric fractures: a retrospective clinical study

Study design awaiting verification · BMC Musculoskeletal Disorders · 2025

Original publication title

Effect of sarcopenia combined with Metabolic Syndrome (MS) on the prognosis of intertrochanteric fractures: a retrospective clinical study

Cheng Zhang; Ding Wang; Xitao Wu; Qinrui Zhang; Lei Chen; Junzhe Lang; Congcong Wu

© The Author(s) 2025

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Sarcopenia significantly worsens postoperative prognosis in elderly intertrochanteric fracture patients, with synergistic deterioration when combined with MS. Chronic inflammation, insulin resistance, and muscle-bone metabolic dysregulation drive adverse outcomes. Comprehensive preoperative screening for sarcopenia and MS, coupled with tailored nutritional support and early rehabilitation, is critical to mitigate complications and improve functional recovery. These findings advocate for integrated care protocols targeting metabolic-musculoskeletal health in geriatric fracture management.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Intertrochanteric fractures pose significant health risks for elderly patients. While metabolic syndrome (MS) and sarcopenia independently impact postoperative outcomes, their synergistic effects on intertrochanteric fracture prognosis remain unclear. This study investigates the individual and combined influence of MS and sarcopenia on complications and functional recovery in elderly patients with intertrochanteric fractures.

Source: Background

Abstract: What methods does the paper describe?

We retrospectively analyzed 460 elderly patients with intertrochanteric fractures, categorized into four groups: control (n = 174), MS (n = 122), sarcopenia (n = 89), and combined (n = 75). Preoperative: perioperative and postoperative data of the MS, sarcopenia, and combined groups were compared with the control group. Primary outcomes included 3-month Barthel Index (BI) and Harris Hip Score (HHS). Multivariate logistic regression identified predictors of poor recovery (HHS < 70).

Source: Methods

Abstract: Results

The MS group had younger patients with higher body mass index (BMI), hypertension, diabetes prevalence, and longer surgery durations (P < 0.05). Sarcopenia and combined groups exhibited lower weight, BMI, handgrip strength (HS), appendicular skeletal muscle mass index (ASMI), and higher American society of Aneshesiologists (ASA) scores (P < 0.05). The MS, sarcopenia, and combined groups had higher incidences of pulmonary infections and pressure ulcers compared with the control group (P < 0.05). The sarcopenia and combined groups also had higher rates of organ failure (P < 0.05), with the combined group showing increased ICU admission (P = 0.003) and in-hospital mortality (P = 0.027).

At three months post-discharge, the sarcopenia and combined groups exhibited higher mortality rates (P < 0.001). At the 3-month follow-up, the sarcopenia and combined groups had significantly lower HHS and BI compared to the control group (P < 0.05). Multivariate logistic regression identified sarcopenia alone (OR 6.50, 95% CI 2.56 to 20.10; P < 0.001) and combined with MS (OR 9.46, 95% CI 3.33 to 34.80; P < 0.001) as significant predictors of poor postoperative recovery.

Source: Results

Abstract: Conclusion

Sarcopenia significantly worsens postoperative prognosis in elderly intertrochanteric fracture patients, with synergistic deterioration when combined with MS. Chronic inflammation, insulin resistance, and muscle-bone metabolic dysregulation drive adverse outcomes. Comprehensive preoperative screening for sarcopenia and MS, coupled with tailored nutritional support and early rehabilitation, is critical to mitigate complications and improve functional recovery. These findings advocate for integrated care protocols targeting metabolic-musculoskeletal health in geriatric fracture management.

Source: Conclusion
Authors’ abstract

Background

Intertrochanteric fractures pose significant health risks for elderly patients. While metabolic syndrome (MS) and sarcopenia independently impact postoperative outcomes, their synergistic effects on intertrochanteric fracture prognosis remain unclear. This study investigates the individual and combined influence of MS and sarcopenia on complications and functional recovery in elderly patients with intertrochanteric fractures.

Methods

We retrospectively analyzed 460 elderly patients with intertrochanteric fractures, categorized into four groups: control (n = 174), MS (n = 122), sarcopenia (n = 89), and combined (n = 75). Preoperative: perioperative and postoperative data of the MS, sarcopenia, and combined groups were compared with the control group. Primary outcomes included 3-month Barthel Index (BI) and Harris Hip Score (HHS). Multivariate logistic regression identified predictors of poor recovery (HHS < 70).

Results

The MS group had younger patients with higher body mass index (BMI), hypertension, diabetes prevalence, and longer surgery durations (P < 0.05). Sarcopenia and combined groups exhibited lower weight, BMI, handgrip strength (HS), appendicular skeletal muscle mass index (ASMI), and higher American society of Aneshesiologists (ASA) scores (P < 0.05). The MS, sarcopenia, and combined groups had higher incidences of pulmonary infections and pressure ulcers compared with the control group (P < 0.05). The sarcopenia and combined groups also had higher rates of organ failure (P < 0.05), with the combined group showing increased ICU admission (P = 0.003) and in-hospital mortality (P = 0.027).

At three months post-discharge, the sarcopenia and combined groups exhibited higher mortality rates (P < 0.001). At the 3-month follow-up, the sarcopenia and combined groups had significantly lower HHS and BI compared to the control group (P < 0.05). Multivariate logistic regression identified sarcopenia alone (OR 6.50, 95% CI 2.56 to 20.10; P < 0.001) and combined with MS (OR 9.46, 95% CI 3.33 to 34.80; P < 0.001) as significant predictors of poor postoperative recovery.

Conclusion

Sarcopenia significantly worsens postoperative prognosis in elderly intertrochanteric fracture patients, with synergistic deterioration when combined with MS. Chronic inflammation, insulin resistance, and muscle-bone metabolic dysregulation drive adverse outcomes. Comprehensive preoperative screening for sarcopenia and MS, coupled with tailored nutritional support and early rehabilitation, is critical to mitigate complications and improve functional recovery. These findings advocate for integrated care protocols targeting metabolic-musculoskeletal health in geriatric fracture management.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12891-025-08931-2.

Publication and source details

Original title: Effect of sarcopenia combined with Metabolic Syndrome (MS) on the prognosis of intertrochanteric fractures: a retrospective clinical study

Cheng Zhang; Ding Wang; Xitao Wu; Qinrui Zhang; Lei Chen; Junzhe Lang; Congcong Wu

BMC Musculoskeletal Disorders · 2025

© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Science and Technology Program of WenzhouY20210435

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T03:49:58.028887+00:00

DOI: 10.1186/s12891-025-08931-2 · PMC12305992